{"id":526482,"date":"2026-06-30T21:20:11","date_gmt":"2026-06-30T21:20:11","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/526482\/"},"modified":"2026-06-30T21:20:11","modified_gmt":"2026-06-30T21:20:11","slug":"timothee-olivier-rasolute-302-daraxonrasib-in-metastatic-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/526482\/","title":{"rendered":"Timoth\u00e9e Olivier: RASolute 302, Daraxonrasib in Metastatic Pancreatic Cancer"},"content":{"rendered":"<p>Timoth\u00e9e Olivier, Medical Oncologist and Attending Physician at the Oncology Division of Geneva University Hospital in Switzerland, shared a post on <a href=\"https:\/\/open.substack.com\/pub\/timotheemd\/p\/rasolute-302-daraxonrasib-in-metastatic?r=8oa3wo&amp;utm_campaign=post&amp;utm_medium=web\" target=\"_blank\" rel=\"noopener nofollow\">Substack<\/a>:<\/p>\n<p>\u201cRASolute 302 (daraxonrasib) in metastatic pancreatic cancer: a revolution?<\/p>\n<p>On April 13, 2026, the company Revolution Medicines announced the positive results of the phase 3 trial RASolute 302 in pancreatic cancer via a press-release (here). The trial was a multicenter global phase 3 trial, conducted in the US, France, Germany, Italy, Japan, Puerto Rico and Spain (see\u00a0here). It included patients with\u00a0metastatic pancreatic cancer\u00a0who had\u00a0previously received one prior line, in the metastatic setting, of therapy with 5-fluorouracil (5-FU) based or gemcitabine-based regimen.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-532233\" src=\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2026\/06\/T-1-800x425.webp\" alt=\"Timoth\u00e9e Olivier: RASolute 302, Daraxonrasib in Metastatic Pancreatic Cancer\" width=\"800\" height=\"425\" title=\"Timoth\u00e9e Olivier: RASolute 302, Daraxonrasib in Metastatic Pancreatic Cancer 2\"  \/><\/p>\n<p>In RASolute 302, patients either received\u00a0daraxonrasib, an oral RAS(ON) multi-selective, non-covalent inhibitor;\u00a0or chemotherapy.<\/p>\n<p>More than 90% of patients with metastatic pancreatic cancer have a RAS mutation with about 85% carrying a KRAS G12 mutation.\u00a0Contrary to other KRAS inhibitors, daraxonrasib inhibits the active RAS(ON) form. Even RAS-wild-type tumors may be dependent on RAS activation, which is the rationale for investigating daraxonrasib beyond RAS-mutant populations.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-532234\" src=\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2026\/06\/T2-1-800x520.webp\" alt=\"Timoth\u00e9e Olivier: RASolute 302, Daraxonrasib in Metastatic Pancreatic Cancer\" width=\"800\" height=\"520\" title=\"Timoth\u00e9e Olivier: RASolute 302, Daraxonrasib in Metastatic Pancreatic Cancer 3\"  \/><\/p>\n<p>The press-release says: \u2018In the overall (intent-to-treat) study population, daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p &lt; 0.0001). Daraxonrasib was generally well tolerated, with a manageable safety profile and with no new safety signals.\u2019<\/p>\n<p>The results will be presented in a few weeks, during\u00a0ASCO2026 plenary session, and a simultaneous publication in the\u00a0New England Journal of Medicine\u00a0would not be surprising.<\/p>\n<p>Most doctors, scientists, and academics\u00a0agree that we should not practice medicine by press release. However, following the RASolute 302 press release, social media and the press have echoed the results, mostly within a one-sided framing and an abundance of superlatives, presenting daraxonrasib as a \u2018miracle\u2019 or a \u2018revolution.\u2019<\/p>\n<p>While doubling median survival in patients with such a poor prognosis is highly unusual, caution is warranted when interpreting any results. Here are some initial thoughts, and what I think we should be looking for during ASCO.<\/p>\n<p>Medicine by press-release? Why this is problematic.<\/p>\n<p>If we look at the toxicity data for daraxonrasib given as monotherapy, as in RASolute 302, data from patients with advanced pancreatic cancer treated in the phase 1\/1b study were reported in a previous Revolution Medicines press-release issued in December 2024.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-532235\" src=\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2026\/06\/T3-1-800x207.webp\" alt=\"Timoth\u00e9e Olivier: RASolute 302, Daraxonrasib in Metastatic Pancreatic Cancer\" width=\"800\" height=\"207\" title=\"Timoth\u00e9e Olivier: RASolute 302, Daraxonrasib in Metastatic Pancreatic Cancer 4\"  \/><\/p>\n<p>A\u00a0quick read gives the false impression that there is minimal grade 3 or higher treatment-related toxicity.<\/p>\n<p>This wording indicates that no individual adverse event exceeded 10% of patients. What is missing from the press-release is that, when taken together, approximately 34% of patients in the 300 mg cohort experienced grade 3 or higher treatment-related adverse events.<\/p>\n<p>In other words, this does not mean low toxicity, but rather distributed toxicity.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-532236\" src=\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2026\/06\/T4-1.webp\" alt=\"Timoth\u00e9e Olivier: RASolute 302, Daraxonrasib in Metastatic Pancreatic Cancer\" width=\"800\" height=\"651\" title=\"Timoth\u00e9e Olivier: RASolute 302, Daraxonrasib in Metastatic Pancreatic Cancer 5\"  \/><\/p>\n<p>Toxicity data will be much awaited from the ASCO 2026 presentation. We can already get a glimpse of how \u2018nasty\u2019 the drug can be. Here, I\u2019m quoting Senator Ben Sasse, who has publicly shared his personal story after being diagnosed with advanced pancreatic cancer and enrolling in RASolute 302.<\/p>\n<p>Ben Sasse : \u2018I take it orally, but it\u2019s a nasty drug. It causes crazy stuff like my body can\u2019t grow skin and so I bleed all out of a whole bunch of parts of me that shouldn\u2019t be bleeding\u2019.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-532237\" src=\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2026\/06\/T5-1-800x504.webp\" alt=\"Timoth\u00e9e Olivier: RASolute 302, Daraxonrasib in Metastatic Pancreatic Cancer\" width=\"800\" height=\"504\" title=\"Timoth\u00e9e Olivier: RASolute 302, Daraxonrasib in Metastatic Pancreatic Cancer 6\"  \/><\/p>\n<p>Former Senator Ben Sasse has given numerous interviews describing what he is going through as a patient with advanced pancreatic cancer. He has explicitly mentioned pain reduction and significant tumor shrinkage, and noted that \u2018this experience has seemingly extended both quantity and quality of life\u2019. At the same time, his public appearances and recounting also highlight the significant toxicities associated with the treatment.<\/p>\n<p>So when we come back to the most recent press release from Revolution Medicine:\u00a0\u2018Daraxonrasib was generally well tolerated, with a manageable safety profile and with no new safety signals.\u2019\u00a0I wonder if patients, including Ben Sasse, would find that this wording is accurately reflecting his and other patients\u2019 general experience.<\/p>\n<p>Medicine by press-release? If we have no choice, let\u2019s do it!<\/p>\n<p>Let\u2019s gather data from the\u00a0press-release\u00a0and from\u00a0clinicaltrials.gov, and let\u2019s see what we can make of it:<\/p>\n<p>the trial included 500 patients, unselected for specific RAS mutations<br \/>\nprimary endpoints = PFS and OS in RAS-G12-mutant patients<br \/>\nsecondary endpoints = OS and PFS in all patients<br \/>\n\u2018Trial met all primary and key secondary endpoints, including progression-free survival and overall survival\u2019<br \/>\n\u2018In the overall (intent-to-treat) study population, daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p &lt; 0.0001).\u2019<br \/>\nStudy start (first patient):\u00a0October 16, 2024;\u00a0Enrollment (500 patients) completed:\u00a0at least in December 2025;\u00a0Total accrual duration:\u00a0maximum 14 months;\u00a0Press release 13 April 2026 (data-cut off likely in March 2026); Maximum follow-up duration about 17 months<\/p>\n<p>The headline OS result is based on a secondary endpoint in the broadest patient population, while the primary endpoints, PFS and OS in the KRAS G12-mutant population, remain unreported<\/p>\n<p>Why the OS estimates in the entire population could be overestimated.<\/p>\n<p>Several factors may have contributed to an inflation of the reported results.<\/p>\n<p>Power is usually calculated for the primary endpoint(s). As such, OS in the ITT population may be insufficiently powered. Additionally, hierarchical testing can reduce the available alpha, effectively reducing power in the ITT analysis.<br \/>\nNested versus adjacent subgroups analyses. As the primary endpoints are in the RAS G12-mutant population, one key question for the overall population is: are non\u2013G12 RAS-mutant patients truly deriving benefit, or is the observed effect in the \u2018overall population\u2019 mainly driven by the G12-mutant population?<br \/>\nEarly stopping rules carry a risk of inflating effect estimates, as shown in empirical work. Were such rules used in RASolute 302?<br \/>\nEfficacy\u2013effectiveness gap? Patients in clinical trials often do not reflect real-world patients, who typically derive less benefit and may experience more toxicity. This is referred to as the efficacy\u2013effectiveness gap. Even if the reported survival benefit is considered reliable, how it will translate into real-world practice remains an open question.<\/p>\n<p>Longer follow-up matters: the NAPOLI-1 example.<\/p>\n<p>Will\u00a0longer follow-up\u00a0data will ultimately be made available. The question is real, as the results are presented as being\u00a0\u2018primary and final\u2019.<\/p>\n<p>To illustrate the effect of longer follow-up, here is the NAPOLI-1 trial as an example, where we have two data points from the 2016 and 2019 reports. NAPOLI-1 was conducted in a setting comparable to RASolute 302. As shown in the estimations below, with longer follow-up, an early separation tends to diminish, with a less pronounced statistical gain.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-532238\" src=\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2026\/06\/t6-1-800x399.webp\" alt=\"Timoth\u00e9e Olivier: RASolute 302, Daraxonrasib in Metastatic Pancreatic Cancer\" width=\"800\" height=\"399\" title=\"Timoth\u00e9e Olivier: RASolute 302, Daraxonrasib in Metastatic Pancreatic Cancer 7\"  \/><\/p>\n<p>\u00a0<\/p>\n<p style=\"text-align: center\">Key questions for ASCO and the full publication:<\/p>\n<p>Statistical details: early stopping rules if specified, alpha spending for each endpoint (particularly the ITT secondary endpoints), number of interim analyses planned, etc.<br \/>\nWhat is the median follow-up and OS maturity, what about censoring?<br \/>\nThe shape of Kaplan\u2013Meier curves: early separation ? curve crossing ? any tail?<br \/>\nITT vs primary endpoints population: how much of the OS benefit in the entire ITT population may have been driven by the prespecified RAS-G12 population<br \/>\nIs the objective response rate (ORR) maintained? In the phase 1\/1b study, the confirmed ORR was 35% in the RAS G12 population and 29% in the overall population. Classically, ORR tends to decrease from early-phase to later-stage studies. As a reminder, sotorasib (a KRAS G12C inhibitor) had an ORR of 37.1% in the early-phase CodeBreaK 100 trial, which later decreased to 28.1% in CodeBreaK 200.<br \/>\nToxicity data!<br \/>\nQuality of life data: if presented: how and when they were measured, compliance rate, timing of measurements, etc.<\/p>\n<p>Long-term efficacy? Drugs facing cancer biology<\/p>\n<p>In 2011,\u00a0George Sledge\u00a0highlighted that the genomic era could bring both promise and chaos. He distinguished\u00a0\u2018stupid\u2019 cancers, like those driven by a single driver mutation, such as chronic myeloid leukemia (CML). In these settings, inhibitors can be transformative: in CML, life expectancy became\u00a0comparable to the general population after the introduction of imatinib.<\/p>\n<p>Yet, most solid tumors are different. They rarely rely on a single driver, and instead harbor co-mutations and\u00a0multiple clones.\u00a0In advanced disease, resistance at some point is the rule rather than the exception.\u00a0Although daraxonrasib does not target a single mutation but rather RAS across multiple contexts, advanced pancreatic cancer remains a biologically\u00a0\u2018smart\u2019 cancer.<\/p>\n<p>To which extent a broad RAS(ON) inhibition can temporarily suppress the genomic and adaptive complexity that usually drives resistance in pancreatic cancer is unclear.<\/p>\n<p>My (temporary) conclusion.<\/p>\n<p>Even though I\u2019m awaiting for the data, I see daraxonrasib as a pharmacological breakthrough, however associated with significant toxicities and inherent biological hurdles when it comes to long-term efficacy.<\/p>\n<p>On social media, discussions have at times become emotional, with any critical appraisal of a trial being perceived as a lack of empathy, which is unfortunate. We should not forget that\u00a0financial stakes are high. Personal stories should not replace careful interpretation of the data.<\/p>\n<p>In oncology, we often say a drug should help patients live longer and\/or better. In the case of daraxonrasib, even with a survival benefit, the toxicity profile and the uncertainty around long-term benefit may make the choice not as straightforward for a fraction of patients.<\/p>\n<p>Whether a treatment that delays, but does not prevent, death, while adding significant toxicity, constitutes a \u2018revolution\u2019 is a question best answered by patients, not by Key Opinion Leaders (KOLs) or companies.\u201d<\/p>\n<p>Other articles featuring <a href=\"https:\/\/oncodaily.com\/tag\/timothee-olivier\" rel=\"nofollow noopener\" target=\"_blank\">Timoth\u00e9e Olivier<\/a> on OncoDaily.<\/p>\n","protected":false},"excerpt":{"rendered":"Timoth\u00e9e Olivier, Medical Oncologist and Attending Physician at the Oncology Division of Geneva University Hospital in Switzerland, shared&hellip;\n","protected":false},"author":2,"featured_media":526483,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[103,61,60],"class_list":["post-526482","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-ie","tag-ireland"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/526482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=526482"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/526482\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/526483"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=526482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=526482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=526482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}